通过对HBV表面抗原表位体E183-91/HLA-A *0201特异的TCR样抗体进行工程设计的CAR-T细胞对HBV-HCC表现出强烈的活性
Fengling Wang1, Jiaqian Li1, Yong Huang1
1Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Oncoimmunology
|August 18, 2025
概括
这项研究设计了仿真抗原受体T细胞 (CAR-T) 来向肝癌中的细胞内HBV抗原. 这种新的方法在临床前模型中证明了抗原特异性杀死,验证了对病毒相关瘤的CAR-T疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 病毒学 病毒学
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法在血液癌症中表现有前途,但由于有限的表面抗原,在固体瘤中面临挑战.
- 通过质主要基因相容性复合体 (pMHC) 结构准细胞内抗原提供了一种扩大CAR-T适用性的策略.
- 与乙型肝炎病毒 (HBV) 相关的肝细胞癌 (HCC) 从集成的病毒DNA中呈现出独特的细胞内标.
研究的目的:
- 设计和评估针对特定细胞内HBV抗原 (Env183-191) 的CAR-T细胞,其呈现的HLA-A*0201.1.
- 评估这些工程CAR-T细胞对HBV相关的HCV的体外和体内疗效和安全性.
- 为在癌症治疗中针对病毒衍生的细胞内抗原提供概念验证.
主要方法:
- 开发使用类似T细胞受体 (TCR) 的抗体对抗HBV Env183-191表型的CAR-T细胞 (HBs183 CAR-T).
- 在体外评估抗原特异性细胞毒性和效应器功能.
- 在皮下和腹腔内异种移植模型中的HBV-HCC体内评估.
主要成果:
- 改造的HBs183 CAR-T细胞表现出特定的识别和杀死呈现HBV Env183-191表位的细胞.
- 在皮下和腹腔内临床前模型中表现出强大的抗瘤活性.
- 预先的安全性概况在体内进行了评估.
结论:
- 设计以向细胞内病毒抗原 (HBV Env183-191) 的CAR-T细胞在临床前环境中对HBV相关的HCC有效.
- 这种方法验证了针对细胞内抗原,特别是病毒表位,用于CAR-T疗法.
- 为HBV-HCC和其他病毒驱动的癌症提出了潜在的治疗策略.
更多相关视频
相关概念视频
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...